S
Sven De Keersmaecker
Researcher at University of Antwerp
Publications - 4
Citations - 91
Sven De Keersmaecker is an academic researcher from University of Antwerp. The author has contributed to research in topics: Cancer & Vaccination. The author has an hindex of 2, co-authored 3 publications receiving 68 citations.
Papers
More filters
Journal ArticleDOI
Cachexia in cancer: what is in the definition?
Greetje Vanhoutte,Mick van de Wiel,Kristin Wouters,Michaël Sels,Linda Bartolomeeussen,Sven De Keersmaecker,Caroline Verschueren,Veronique De Vroey,Annemieke De Wilde,Elke Smits,Kin Jip Cheung,Liesbeth De Clerck,Petra Aerts,Didier Baert,Caroline Vandoninck,Sofie Kindt,Sofie Schelfhaut,Marc Vankerkhoven,Annelies Troch,Lore Ceulemans,Hanne Vandenbergh,Sven Leys,Tim Rondou,Elke Dewitte,Kristel Maes,Patrick Pauwels,Benedicte Y. De Winter,Luc Van Gaal,Dirk Ysebaert,Marc Peeters +29 more
TL;DR: A correlation with prognosis in favour of Evans et al’ definition as a tool for cachexia diagnosis is presented, which means that weight loss and BMI decline are both key factors in patients with cancer leading to cachexia but less decisive as stated by Fearon et al.
Journal ArticleDOI
Prescreening for COVID-19 in patients receiving cancer treatment using a patient-reported outcome platform.
Marc Peeters,Peter van Dam,Marika Rasschaert,Christof Vulsteke,Sven De Keersmaecker,Lieselot Croes,Ilse Van Brussel,Jo Ravelingien,Annelies Janssens,Hans Prenen +9 more
TL;DR: One of the strategies to treat patients with cancer as safe as possible is to reduce hospital visits to a strict minimum, and this work has previously reported on AMTRA.
Journal ArticleDOI
Antibody Response after BNT162B2 COVID-19 mRNA Vaccination in Cancer Patients Under Anti-Neoplastic Treatment
Marc Peeters,Lise Verbruggen,Laure-Anne Teuwen,Greetje Vanhoutte,Sara Vande Kerckhove,Bart Peeters,Silke Raats,Isolde Van der Massen,Sven De Keersmaecker,Manon T. Huizing,Pieter Pannus,Kristof Y. Neven,Kevin K. Ariën,Geert A. Martens,Marc Van Den Bulcke,Ella Roelant,Isabelle Desombere,Sébastien Anguille,Maria E Goossens,Timon Vandamme,Peter van Dam +20 more
TL;DR: The BNT162b2 COVID-19 vaccine is well-tolerated in cancer patients under active treatment, however, the antibody response of immunized cancer patients was delayed and diminished, mainly in patients receiving chemotherapy or rituximab, resulting in breakthrough infections.
Journal ArticleDOI
Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors
Angelina Konnova,Fien H. R. De Winter,Lisanne C Verbruggen,An Hotterbeekx,M. Berkell,Laure Anne Teuwen,Greetje Vanhoutte,B. Peeters,Silke Raats,Isolde Van der Massen,Sven De Keersmaecker,Y. Debie,M. T. Huizing,Pieter Pannus,Kristof Y. Neven,K. K. ArieÌn,Geert A. Martens,Marc Van den Bulcke,Ella Roelant,Isabelle Desombere,Sébastien Anguille,Zwi N. Berneman,M. Goossens,Herman Goossens,Surbhi Malhotra-Kumar,E. Taconelli,Timon Vandamme,Marc Peeters,P. V. van Dam,Samir Kumar-Singh +29 more
TL;DR: In this article , the authors employed machine learning approaches to identify a biomarker signature based on blood cytokines, chemokines, and immune-and non-immune-related growth factors linked to vaccine immunogenicity in 199 cancer patients receiving the BNT162b2 vaccine.